EMJ 3.2 has entered the building! This truly multidisciplinary eJournal returns for its 10th issue and its second of 2018. EMJ 3.2 includes a plethora…

A clinical scale that takes a broader, deeper view of Parkinson’s disease (PD) symptoms is the latest milestone in a collaborative effort by My PD…

The current treatment strategy for patients with inflammatory bowel disease (IBD) aims to enable physicians to deliver optimal care and to improve the…

This publication covers the first session of Almirall’s 11th Skin Academy meeting in Barcelona, Spain. This year, the meeting theme was ‘The Science of…

Biosimilars have contributed substantially to the evolving therapeutic landscape for inflammatory bowel disease (IBD), enabling healthcare systems to…

Gastric cancer is the second most common cause of cancer-related deaths worldwide, and the 5-year overall survival rate for advanced gastric cancer is ≤25%.

The prevalence of respiratory diseases, including asthma and chronic obstructive pulmonary disease, has increased in recent decades, placing a…

With the recent growth in oral anticancer agents (OAA), pharmacists working in the community have recognised the urgent need to develop safe and…